Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
about
Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspectivePretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case reportThe impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximabRole of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of carePrediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study.Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaAutologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Accelerated therapeutic progress in diffuse large B cell lymphoma.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Autologous hematopoietic cell transplantation: an update for clinicians.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?Evolution of lymphoma staging and response evaluation: current limitations and future directions.Adolescent and young adult non-Hodgkin lymphoma.There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCTImpact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patientsEfficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
P2860
Q26998446-3FE288E6-ACBA-4E0C-B9B8-D8C1C436D965Q30240084-59268C0C-554F-4195-AEFE-A00041609D96Q30240133-18678118-72BC-483F-B04D-7A9522403283Q33716674-B4D1D925-B3D5-4B8B-A21C-81309782ED2BQ33978922-EFF08265-038D-4A58-99A4-C61A06CFE990Q34314074-F7E6AF41-FD91-4CA6-8912-5E958A5DAC4CQ35525404-0F48686D-9762-4F5E-8F86-A307DE7E6679Q35626262-74DAE407-AAD2-4BCC-A6EA-FC9F484EC56BQ35776255-C47A2144-F8B2-447E-8FF9-3785C34DA4CCQ36128165-07A1C87C-A056-434B-8804-8D957F9F9C4EQ37020999-DA024A05-5665-478E-9540-02AC0A455EEBQ37021454-2C444EC0-DCC3-4C98-A660-E35D671D174EQ37425998-D87250F8-B595-4FB7-A8D8-1722DAE89C45Q37613310-30C3BCB5-0243-4EA6-B93C-A99F9E40DFF4Q37618909-186B2709-3653-45C4-9618-5E4DE7ED9C7CQ37695075-6D7CD106-80AD-4ED0-9164-483902FD96BBQ38138170-320E49F1-3452-40E6-A46B-F880B1F1BFDCQ38161760-B021AA5A-3D51-4AAA-8A5F-97E3AF9EF1D9Q38174498-DCE1DA06-B419-430D-A0D7-2DDA8F6AF8F6Q38179500-8F48F2B6-FBE8-4DE3-8F3E-E2CF5D0C71EEQ38190105-CD511EA9-9944-4410-8548-C699F260FBE1Q38248359-EB5CE7E2-6F77-4284-9266-8C3CDA2895ACQ38387292-63FF6236-6D02-4B22-A276-D5694F24DD19Q38465823-82B1A409-5996-4729-9B84-8F1825B172B1Q38530254-253D6E15-DC4F-4A80-8046-A5714C0A772CQ38629758-4CF69F7A-A644-4706-9C69-53C274DA370BQ38656983-6AF1AC5F-79E9-4C38-9ADA-6DD9AD123B9CQ38671671-C9E18130-CF40-4B59-9FFD-8B94AB8ADA75Q38806478-D4C1F13C-3B84-4DBB-B27A-85C0655D612CQ39586919-A38BFF5B-0398-4E29-8D26-C9AFB6AFF266Q39669214-919CC8F5-816F-4819-B125-319C34AFDAD3Q40356629-E61BE7C4-304C-45B3-BC0E-D97CFC5D8FECQ40507970-3ED8C383-56DF-41F3-A05C-93126FD2927FQ40680175-E45FB8FF-068A-42FB-9D4C-B4637E9678ECQ40797419-C3179560-F8AA-40F1-B1BE-AB702CDF7D00Q41361615-A44B883E-AE18-416B-A302-F90BC9680D57Q42700683-2FBEFB3C-2C74-4A0B-8F48-FB58E0C88723Q43924146-43B0DDE2-3E32-45EA-91D1-556BD8087710Q43930995-60F679A3-37B8-40FD-B819-B3C5B473E9C2Q44220436-C72D789C-E15B-4106-B851-EF89BB4FD015
P2860
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@ast
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@en
type
label
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@ast
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@en
prefLabel
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@ast
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@en
P2093
P1433
P1476
Conventional chemotherapy (CHO ...... phase 3 trial (DSHNHL 2002-1).
@en
P2093
Andreas Rosenwald
Andreas Viardot
Bertram Glass
Christian Ruebe
Christian Schmidt
German High-Grade Lymphoma Study Group (DSHNHL)
Gottfried Doelken
Lorenz Truemper
Maike Nickelsen
Marita Ziepert
P304
P356
10.1016/S1470-2045(12)70481-3
P577
2012-11-16T00:00:00Z